rituximab rheum
Selected indexed studies
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. (Arthritis Rheum, 2012) [PMID:22231479]
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (Ann Rheum Dis, 2024) [PMID:37827694]
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (Ann Rheum Dis, 2024) [PMID:36927642]
_Worker-drafted node — pending editorial review._
Connections
rituximab rheum is a side effect of
Sources
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (2024) pubmed
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. (2023) pubmed
- Update οn the diagnosis and management of systemic lupus erythematosus. (2021) pubmed
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. (2012) pubmed
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. (2013) pubmed
- Rituximab-induced serum sickness: A systematic review. (2015) pubmed
- Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). (2018) pubmed
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. (2010) pubmed
- EULAR recommendations for the treatment of systemic sclerosis: 2023 update. (2025) pubmed